Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Julie N. Graff, Joshi J. Alumkal, Charles G. Drake, +8

Oncotarget

A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer

Joshi J. Alumkal, Rachel Slottke, Jacob Schwartzman, +12

Investigational New Drugs

UrologyMedicinePathologyPhase Ii StudyProstatic Disease +2

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

Julie N. Graff, Tomasz M. Beer, Joshi J. Alumkal, +11

Journal for ImmunoTherapy of Cancer

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

Andrew J. Armstrong, Susan Halabi, Patrick Healy, +11

European Journal of Cancer

UrologyPhase Ii TrialMedicinePharmacologyPharmacotherapy +4

Gene expression profiling of whole blood: Comparison of target preparation methods for accurate and reproducible microarray analysis

Kristina Vartanian, Rachel Slottke, Timothy G. Johnstone, +6

BMC Genomics

Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab)

Lauren B. Peiffer, James R. White, Carli B. Jones, +5

Neoplasia

Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up.

Julie N. Graff, Joshi J. Alumkal, Reid F. Thompson, +6

Journal of Clinical Oncology

UrologyGenitourinary CancerMedicineDna Repair DefectsPharmacology +11

First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC)

Julie N. Graff, Joshi J. Alumkal, Charles G. Drake, +5

Annals of Oncology

UrologyOncologyGenitourinary CancerFirst EvidenceMedicine +7

Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer

Jennifer Podolak, K. M. Eilers, Timothy A. Newby, +11

Oncotarget

Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).

Andrew J. Armstrong, Susan Halabi, Patrick Healy, +8

Journal of Clinical Oncology

Androgen ReceptorUrologyOncologyPhase Ii TrialMedian Composite Pfs +7